Janus International Group (JBI) has caught the attention of investors after S&P Global Ratings upgraded the company’s credit rating from "B+" to "BB-" with a stable outlook. This shift highlights the company’s steady business model, low net leverage, and reliable cash flow.
See our latest analysis for Janus International Group.
The S&P rating upgrade comes on the heels of upbeat quarterly earnings and a $75 million share repurchase program, both of which signal management’s ongoing...
This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos
Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals.
See our latest analysis for Perspective Therapeutics.
This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...
Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication.
This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy.
We'll explore how Fast Track status for AlloNK and...
As the Dow Jones Industrial Average reaches an all-time high amidst a flurry of corporate earnings reports, investors are keenly observing the broader U.S. market's performance against a backdrop of ongoing government shutdown and trade discussions with China. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities that may arise from discrepancies between current stock prices and their intrinsic value.
As the Dow Jones Industrial Average reaches an all-time high amid a flurry of robust earnings reports, the broader U.S. market is experiencing a wave of optimism despite ongoing economic challenges such as the government shutdown. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding, especially as investors look beyond well-known names to uncover hidden opportunities within the market.
